Slate360 Provides Insights on Innovations in Tradeshow Booth Design from Concept to Approved Design with AI as a Copilot
From a science fiction concept to a powerful tool leveraged by creative professionals, AI has come a long way in a short time. While some are putting off their use of AI as long as possible for various reasons, at Slate360, we're embracing it to enhance our creative process, work more efficiently, and collaborate more effectively with our clients.
We have found that using AI tools in our booth design process, in particular, accelerates ideation, giving us and our clients more time to consider a wider array of concepts. As a result, they tend to view the design they ultimately choose as the best possible solution for meeting their needs and making their tradeshow appearances even more beneficial.
While future articles will address how companies can use AI to increase in-booth engagement, improve data capture and analysis, and other related topics, this one focuses on how and why AI is so helpful in the booth design process.
Tradeshow Booth Design: The Foundation of Productive Interactions
Before diving into the design process, it's important to consider why tradeshow booth design matters. Someone new to tradeshows in general and healthcare tradeshows in particular might understandably think, 'The booth is just where you meet with people. What's most important is the products and services a company offers.'
It's true that a company's offerings are a primary driver of booth traffic and engagement. If your products or services aren't meeting attendees' needs or are viewed as inferior or ineffective, no booth design is going to convince people to talk with you about them. However, assuming you have excellent offerings, a well-designed booth can act as a magnet, drawing show attendees in and encouraging them to engage with your brand.
As experienced marketers can attest, often, the difference between someone becoming a customer or walking away uninterested is that light that goes on in their mind when they view a compelling piece of content, engage with an interesting and informative display, etc. There truly are multiple make-or-break moments as an attendee considers a company's products at a tradeshow.
A thoughtfully developed booth design plays a pivotal role in tilting the odds in the business's favor.
From Concept to Approved Design: AI as Our Copilot
To be clear, involving AI in developing tradeshow booth designs doesn't mean allowing it to drive the process. Instead, using AI empowers our skilled and experienced designers with powerful tools that help them reach critical insights.
Having AI as a 'copilot' provides (or will soon offer) multiple benefits, including:
If you've ever been in a creative brainstorming meeting, you know that it can involve all kinds of exercises to get the creative juices flowing and help the participants reach a shared mental model. The sessions can be very effective, but they take time.
AI does something similar but in a matter of seconds, considering user prompts and an array of inputs, including images of a client's existing tradeshow properties and others they like, to generate the requested number of concepts for consideration. Designers and company stakeholders can then discuss these concepts and have AI iterate further—in real time—on any that seem promising, repeating the process until participants land on one or a few ideas that the design team will explore further.
AI tools can be used in all phases of ideation, from mood board creation to booth concept development, and they can even leverage rough inputs like simple sketches to create gorgeous, lifelike images. Capitalizing on their impressive processing power can be a huge time-saver.
The best booth designs are informed by client preferences but also results from past tradeshows. AI will increasingly capitalize on vast datasets from events to provide recommendations on how a booth can best attract attendees and support a company's marketing strategy and sales efforts.
The predictive analytics capabilities of AI tools will continue to take more of the guesswork out of booth design. As a result, it will empower design teams to replace statements like, 'We believe these design features will engage your target audience effectively,' with 'The data tells us you'll get the best results with these design features.'
We'll expand on this concept in future articles, but success at healthcare tradeshows rides on a company's ability to deliver relevant and targeted information to attendees. AI can help create booth designs that support those goals.
After ideation and concept selection, AI helps refine rough concepts into fully realized designs. Tools can be used to integrate input from our designers, booth construction experts, and clients to create a design that is eye-catching and helps the client achieve their tradeshow goals while also being executable in the real world.
From 3D renderings to virtual walkthroughs, AI can produce deliverables that enable faster feedback and better decision-making, resulting in a smoother and more efficient design process.
By optimizing the design process and reducing the need for multiple physical prototypes, AI tools can help companies save money on concept development and booth design. AI can also assist in identifying and vetting the latest eco-friendly practices in tradeshow booth creation, including providing insights on sustainable materials and waste reduction.
AI in Tradeshow Booth Design: Looking Ahead
One of the most remarkable things about AI is its exponential growth. AI tools are learning and evolving at a rate humans almost can't comprehend, so it's impossible to say where the technology will be even a year from now.
Our approach—and our advice to clients—is to be as open-minded and flexible as possible. Of course, that doesn't mean abandoning critical thinking. The companies behind AI tools, like all companies, will likely make certain promises their products can't keep. So, while we eagerly anticipate each advance in AI technology, we're focused on only adding to our toolkit the products that improve our design processes and deliver value to our clients.
That said, the future of AI in healthcare marketing is bright!
At Slate360, we're excited about the possibilities AI presents in helping healthcare organizations stand out in a competitive landscape, ensuring their brand messages resonate and their tradeshow investments produce exceptional returns.
If you're looking to enhance your tradeshow strategy by creating a new tradeshow booth or modifying an existing property, we encourage you to contact us. Together, we can explore how an AI-powered design can transform our shared vision into a reality.
About Slate360
Our team of seasoned healthcare industry pros crafts unique, immersive exhibit experiences that attract attendees and create lasting impressions of clients and their offerings. We work as an extension of a client's team to streamline strategy development, execution, and analytics and to ensure an onsite or virtual trade show presence furthers their marketing objectives. https://slate360inc.com/
Slate360 Media Contact
Pam Laferriere, 657-204-1916
Source: Story.KISSPR.com
Release ID: 1650617
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
23 minutes ago
- Wall Street Journal
Unemployed Americans Endure Longer Job Searches in a Cooling Market
Job seekers are out in the cold this summer. Especially the ones who have been hunting for a while. Beyond the headline-grabbing top-line numbers in the jobs report for July was another striking piece of data: The number of people unemployed for at least 27 weeks topped 1.8 million, the highest level since 2017, not counting the pandemic's unemployment surge. The median length of unemployment in the U.S. has also ticked up, from a seasonally adjusted 9.5 weeks in July 2024 to 10.2 weeks last month.
Forbes
23 minutes ago
- Forbes
Trump Says He Will Get Drug Prices Down By 1500%
U.S. President Donald Trump is now promising to get pharmaceutical companies to significantly reduce the drug prices that they are charging Americans. On Thursday, the White House announced that Trump had just sent letters to the heads of 17 major pharmaceutical companies pushing them to cut the prices that Americans have to pay down to the levels that people in other countries pay. It's not clear yet by what amount—if any—this will eventually get pharmaceutical companies to reduce prescription medication prices for those in the U.S. But chances are any price reductions that end up occurring won't be anywhere near the 1500% that Trump has promised. Trump Spoke Of 600%, 1000% And 1500% Reductions in Drug Prices Yep, 1500% is the percentage that Trump mentioned in a July reception with members of Congress. 'This is something that nobody else can do,' Trump emphasized then. "We're gonna get the drug prices down. Not 30 or 40 percent, which would be great, not 50 or 60, no. We're gonna get 'em down 1,000 percent, 600 percent, 500 percent, 1,500 percent.' Here's a video of this posted on what used to be Twitter: Getting the prices of medications—or of anything that's sold by companies for that matter—down by more than 100% is certainly something that no one else has done. It's probably something you have never even dreamed of before, since for-profit companies are usually trying to make, you know, a profit. So, it's kind of true what Trump then subsequently said, 'We will have reduced drug prices by 1,000 percent, by 1,100, 1,200, 1,300, 1,400, 700, 600; not 30 or 40 or 50 percent but numbers the likes of which you've never even dreamed of before.' A video of this was also posted on X: Let's do the math. Say a bottle of a medication currently costs $100. A 25% price reduction would bring this cost down to $75. A 100% price reduction would make the medication completely free. Any reduction greater than 100% would presumably mean that the manufacturer would have to pay you. Thus, a 200% price reduction would result in a $100 payday per bottle for you. Holy, new way to earn money, Batman! If Trump can get you a 1500% reduction, hallelujah, time to replace filming YouTube videos with 'buying' medications as the way to make money. Now, the chances that the Trump administration will achieve a 1500% reduction in drug prices are probably a whole lot less than 100%. Getting pharmaceutical companies who have been enjooying very healthy profits for years to pay customers to take their drugs would be quite a trick. Plus, the pharmaceutical companies would have to change their advertisements so that instead of telling you that you may have a condition that you don't realize you have, the ads might say something like 'You're fine and don't have anything that pharmaceutical interventions can't fix. Please don't use our medications. We can't afford you to do so.' Trump Sent Letters To 17 Pharmaceutical Companies Outlining Steps To Reduce Drug Prices That 1500% number may not have been in the letters that Trump sent on Thursday to pharmaceutical manufacturers. Assuming that the letters had the right postage, they went to the leaders of AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. According to the White House, the letters listed steps to reduce the prices of prescription drugs in the U.S. 'to match the lowest price offered in other developed nations (known as the most-favored-nation, or MFN, price)' The steps are as follows: The letters asserted that there's been 'global freeloading on American pharmaceutical innovation' and did warn that if the outlined steps were't taken by the pharmaceutical companies the federal government "will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices." Trump Signed An Executive Order Regarding Drug Prices In May Pharmaceutical companies can now be 1500% sure that the Trump administration has them in its political line-of-sight. Back on May 12, Trump signed an Executive Order that asserted the following: 'The United States has less than five percent of the world's population and yet funds around three quarters of global pharmaceutical profits. This egregious imbalance is orchestrated through a purposeful scheme in which drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States.' That Executive Order indicated that the U.S. Secretary of Health and Human Services, which is currently Robert F. Kennedy, Jr., 'shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' Americans Do Pay Higher Drug Prices Than Those In Other Countries It is true that drug prices are typically significantly higher in the U.S. than in other countries. For example, a June 2024 publication in the RAND Health Quarterly described how drug prices in the U.S. were on average nearly three times higher than those in 33 other high-income countries. Over the past two decades, yearly rises in drug prices have easily outpaced inflation. A 2024 KFF poll showed that the majority of Americans are worried about prescription medication costs being too high. Such worries shouldn't be that surprising. Many prescription medications are not like mullets or fruitcakes. Taking them is often not a choice. Your well-being and even your life could literally depend on being able to afford the medication. And many pharmaceutical companies have shown no qualms about raising the price of medications as soon as they can. For example, even after receiving substantial funding from the U.S. government, Pfizer and Moderna quickly raised the prices of their COVID-19 vaccines as soon as the government wouldn't completely pay for them, as I described in Forbes in 2023. It is also true that talk about drug prices being too high in the U.S. is not new. Yet, none of the Presidential Administrations over the past two decades have done much to significantly alter these trends. I've written about state-wide efforts to reduce drug prices, such as Propostion 61 in California. But there's been a lack of more comprehensive efforts at the federal level to do so. The challenge is that a number of trends in the current U.S. system are contributing to higher drug prices. For example, mergers and acquisitions over the years have led to fewer, larger and more dominant pharmaceutical companies with less competition. Existing cost structures and requirements make it more difficult for new pharmaceutical companies to emerge and provide more competition. Cuts in funding and support for scientific research has made it harder and harder to develop new products. Fewer new products leave patients with fewer alternatives and existing products with less competition. Consumers and different purchasers have lacked negotiating power in general. At the same time, it seems like more and more people have been getting pieces of the drug price pie. This has included various middle people such as pharmacy benefits managers and different administrators. The marketing budgets of pharmaceutical companies have continued to grow as well. On top of that, investors have expected pharmaceutical companies to have ever increasing profitability. All of this means that a single simple intervention probably has a small percentage chance of reducing drug prices in a sustainable manner. Instead, a system approach may be needed, meaning multiple interventions at different points in the system that work together in a coordinated manner. Otherwise, there may be unintended consequences. A sustainable reduction in drug prices means one in which the math works out for all patients. You don't want a situation where the prices of some drugs are reduced while those of others are raised. You also don't want a situation where the costs end up being hidden.
Yahoo
39 minutes ago
- Yahoo
Trump fires Bureau of Labor Statistics commissioner after weak jobs report
The president fired the commissioner on Friday after a weaker-than-expected July jobs report showed hiring slowed with only 73,000 new jobs created, and revisions revealed hiring in May and June was much less than initially reported.
